EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients - Targeting a $10 Billion Drug Resistance Market Zero Grade 3+ Toxicities associated with ENV-105 in 13 Patients; ENV-105 (Carotuximab) Demonstrates Clean Safety Profile in Combination with Osimertinib (AstraZeneca’s Tagrisso®) - Advancing Kairos’s Mission to Resensitize the Largest Unmet Need Population in Lung Cancer LOS ANGELES - July 15, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca’s Tagrisso®) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The data represent a pivotal milestone in Kairos Pharma’s lead program: resensitizing patients who have acquired resistance to osimertinib, the global standard-of-care for EGFR-mutated NSCLC. With no serious adverse events (Grade 3 or higher) observed across 13 treated patients to date from ENV-105 tr…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Kairos Pharma, Ltd.
KAPANYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01. Other Events. On July 15, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release reporting interim safety data from the Company’s ongoing Phase 1 clinical trial evaluating ENV-105 (Carotuximab), in combination with osimertinib, in patients with advanced EGFR-mutated non-small cell lung cancer. A copy of the press release is furnished herewith as Exhibit 99.1.…
Recent company filings
- Regulation FD DisclosureSep 14, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 21, 2026
- 10-Q filingAug 12, 2026
- Entry into a Material Definitive Agreement · Other EventsJul 22, 2026
- Submission of Matters to a Vote of Security HoldersJun 30, 2026
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01.
Other Events.
On
July 15, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release reporting interim safety data from the Company’s
ongoing Phase 1 clinical trial evaluating ENV-105 (Carotuximab), in combination with osimertinib, in patients with advanced EGFR-mutated
non-small cell lung cancer. A copy of the press release is furnished herewith as Exhibit 99.1.
The
information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed
“filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be
incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.